Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given an average rating of “Moderate Buy” by the ten ratings firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $19.00.

FULC has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, January 22nd. Stifel Nicolaus set a $25.00 target price on Fulcrum Therapeutics in a research report on Monday, December 8th. Bank of America lifted their target price on Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a report on Tuesday, December 9th. Wall Street Zen lowered Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. Finally, Royal Bank Of Canada raised their price objective on Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a “sector perform” rating in a research report on Monday, December 8th.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC opened at $8.04 on Friday. The company has a 50 day simple moving average of $8.90 and a 200 day simple moving average of $9.61. The firm has a market cap of $535.46 million, a PE ratio of -6.81 and a beta of 3.27. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Tuesday, February 24th. The company reported ($0.31) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.31). As a group, research analysts anticipate that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $30,000. Quarry LP acquired a new stake in shares of Fulcrum Therapeutics during the third quarter worth $35,000. Meeder Asset Management Inc. acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth $39,000. Russell Investments Group Ltd. raised its stake in Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after buying an additional 9,092 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its stake in Fulcrum Therapeutics by 108.3% during the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after buying an additional 3,697 shares during the last quarter. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.